This clinical trial is focused on studying the safety of shortened infusion times for various cancer treatments known as monoclonal antibodies. These treatments include nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab, atezolizumab, and rituximab. Monoclonal antibodies are a type of protein made in the lab that can bind to substances in the body, including cancer cells. The purpose of the study is to determine how often and how severe infusion-related reactions occur when these medications are given more quickly than usual.

Participants in the study will receive one of the mentioned treatments through an intravenous infusion, which means the medication is delivered directly into a vein. The study will observe and record any reactions that occur during these faster infusions. These reactions can include symptoms like fever, chills, or rash, which are sometimes experienced when the body responds to the medication. The study will compare these reactions to those recorded in past treatments where the infusions were given at a standard pace.

The study will continue over a period of time, with participants receiving their treatments and being monitored for any side effects. The goal is to gather information on whether these faster infusions are safe and to understand the experiences of patients undergoing these treatments. This information could help improve the way these cancer therapies are administered in the future, potentially making them more convenient for patients. The study will also look at other factors such as the effectiveness of the treatment and the overall experience of the patients involved.